More on Sangamo

Sangamo BioSciences' (SGMO) first clinical study, a phase 1 trial conducted on six HIV-positive patients over 12 weeks, demonstrates that the T-cell genome can be safely engineered to mimic a naturally occurring mutation that provides resistance to HIV infection. This could potentially be a way to control HIV infection without the use of drugs.

In the study, T-cells from the subjects were isolated and edited with ZFNs to make them resistant to the HIV virus by knocking out the CCR5 gene that encodes a coreceptor required for infection. The altered cells, SB-728-T, were returned to the subjects via autologous infusion.

The ZFN-modified cells showed preferential survival over unmodified cells and were able to persist and circulate throughout the body to key reservoirs of HIV infection such as gut-associated lymphoid tissue.

Shares are up 14% in early trading.

From other sites
Comments (1)
  • Pelion
    , contributor
    Comments (61) | Send Message
    Same research team and headline dates back to 2011:


    Not much new here.
    6 Mar 2014, 10:31 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs